Monoclonal antibodies to taxanes that neutralize the biological activity of paclitaxel.
Recently it has been proposed that drug-specific neutralizing antibodies may limit side-effects that occur during chemotherapy. These studies were undertaken to determine if monoclonal antibodies, 3C6 specific to paclitaxel and 8A10 specific to taxane diterpenes, are inhibitors of paclitaxel-induced inhibition of proliferation and cellular microtubule and nuclear changes. The results show that 3C6 and 8A10 each inhibit paclitaxel-induced cytotoxicity, microtubular bundling, stabilization from vinblastine-induced microtubule depolymerization and the formation of micronuclei. We conclude that these antibodies effectively neutralize paclitaxel activity in vitro and that they may be useful to determine if antibody-blocking strategies can prevent dose-limiting toxicities.
Bignami
G S
GS
Hawaii Biotechnology Group, Inc., Aiea 96701, USA. gbignami@hibiotech.com
Mooberry
S L
SL
D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D000918:Antibody Specificity; D000972:Antineoplastic Agents, Phytogenic / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008870:Microtubules / Q000187:drug effects* / Q000502:physiology; D017239:Paclitaxel / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000494:pharmacology; D014407:Tumor Cells, Cultured / Q000187:drug effects
D000911:Antibodies, Monoclonal; D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel